c-MET is overexpressed in carcinomas and other solid tumors such as small cell lung cancer in human,[29] ovarian tumors,[30] esophageal cancer,[31] and GBM.[32] Therefore, efficient compounds inhibiting c-MET can be exploited therapeutically. This evidence concerns the gene MET and glioblastoma.